secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001493152-25-007094
Event type: regulatory
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed regains Nasdaq compliance after equity actions; enters 1-year monitoring
-------------------------------------------------------------------------------

- Notified Feb 14, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) ($2.5M equity).
- Regained compliance via exchange of $22.3M notes for Series C preferred, $2.653M new preferred issuance, and Lucid Diagnostics deconsolidation.
- Subject to one-year Mandatory Panel Monitor until Feb 14, 2026; new deficiency could trigger delisting.
- Company previously received hearing panel extension to Jan 31, 2025 after failing market value rule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315225007094/0001493152-25-007094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315225007094/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-007094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer